Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2002

View Archived Issues

Efficacy of HCT-1026 as a treatment for overactive bladder in women

NS-8 reverses bladder hyperactivity in rats without affecting blood pressure or heart rate

Rho/Rho kinase pathway involved in spontaneous myogenic tone of isolated pig urethra

Enrollment completed in Repel-CV trial

Xention Discovery created following CeNeS technology acquisition

Kirin initiates phase II Mylovenge trials in Japan

TLK-286 to enter phase III by first quarter 2003

Ark and Tanabe collaborate on cachexia product development

Lexapro launched for major depressive disorder

Eligard 22.5 mg launched

Rosuvastatin: superior cholesterol control compared to atorvastatin and potential in stroke

IL-10 gene transfer suppresses autoimmune myocarditis in Lewis rats

Data presented at ESC 2002 support further clinical evaluation of AR-C69931MX in myocardial ischemia

ATL-962 significantly increases fat excretion in phase Ib studies

Improved oral bioavailability achieved in dihydropyridine Y1 receptor antagonists

Potent and orally active Lck inhibitors with activity in animal models of T-cell activation

Phase III Cidecin trial in endocarditis and bacteremia enrolls first patients

Symlin dose-titration study fully enrolled

Bay-43-9006 enters phase II

Arimidex approved in early breast cancer

Sumitomo presents novel agents for arthritis and bone disorders

New bronchodilators prepared and tested at Mercian

Novel inhibitors of VEGF expression covered by Mercian patent

New adenosine A2A antagonists and their use in Parkinson's disease described by Vernalis

Novel NOS inhibitors in early development at Fujisawa

Novel COX-1 inhibitors with analgesic activity described by Fujisawa

Novel antitumor compounds isolated from Clavularia corals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...